ARST1431: A Randomized Phase 3 Study of Vincristine Dactinomycin Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI Torisel NSC# 683864 IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Intermediate Risk Rhabdomyosarcoma
  • Age: Between 1 - 40 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients with newly diagnosed RMS of any subtype, except adult-type pleomorphic. 2. Patients must have sufficient tissue available for the required biology study. 3. Feasibility Phase: Patients must be < 21 years of age at the time of enrollment. Efficacy Phase: Patients must be = 40 years of age at the time of enrollment.

You may not be eligible for this study if the following are true:

  • 1. Patients who have previously received TORI, another mTOR inhibitor, or any other investigational agent. 2. Patients who have received any chemotherapy (excluding steroids) and/or radiation therapy prior to this enrollment. 3. Patients with uncontrolled hyperglycemia. Patients with uncontrolled hyperlipidemia.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.